Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2022-10-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于恩威医药股份有限公司使用募集资金向全资子公司提供无息借款实施募投项目的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of raised funds by Enwei Pharmaceutical Co., Ltd. to provide interest-free loans to its wholly-owned subsidiary for investment projects. It references regulatory approvals, fundraising details, project investment amounts, board and independent director approvals, and the sponsor's verification opinion. The document is not a financial report itself but a regulatory compliance and verification statement related to the use of fundraising proceeds. It does not contain financial statements or earnings data but focuses on the regulatory and procedural aspects of fund usage. The document length is 3526 characters, which is relatively short and consistent with a regulatory or compliance filing rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related verification opinion and not a full financial report or announcement of a report.
2022-10-26 Chinese
公司信息披露事务管理制度
Governance Information Classification · 100% confidence The document is titled as an "Information Disclosure Management System" for a company, detailing the rules, responsibilities, and procedures for information disclosure. It references regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange, and covers topics like periodic reports (annual, semi-annual, quarterly), temporary reports, major events disclosure, insider information management, and responsibilities of directors and officers. The document is a governance and compliance manual rather than an actual financial report or announcement. It does not contain financial statements, earnings data, or audit opinions. It is a detailed governance document about how the company manages information disclosure obligations. Therefore, it fits best under Governance Information (CGR).
2022-10-26 Chinese
公司投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" for a company, detailing policies, principles, and procedures for managing investor relations. It includes sections on communication with investors, information disclosure, investor meetings, and regulatory compliance. There are no financial statements, earnings data, or audit information. It is a governance-related document outlining internal rules and practices for investor relations management. It is not a report of financial results, audit, or legal proceedings, nor is it an announcement or transcript. Therefore, the document best fits the category of Governance Information (CGR). The document length (6449 characters) and content confirm it is a substantive policy document, not a brief announcement or certification.
2022-10-26 Chinese
公司内幕知情人登记管理制度
Governance Information Classification · 95% confidence The document is titled as an "Insider Information Insider Registration Management System" for Enwei Pharmaceutical Co., Ltd., approved by the company's board of directors. It details the company's internal policies and procedures for managing insider information, including definitions, responsibilities, registration, confidentiality, and reporting requirements. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes internal governance rules and compliance procedures rather than financial data, earnings, or audit results. It is a governance-related internal policy document rather than a financial report, announcement, or regulatory filing. Therefore, the most appropriate classification is Governance Information (CGR).
2022-10-26 Chinese
独立董事关于第二届董事会第十一次会议审议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters reviewed at the company's second board meeting, specifically regarding the use of raised funds for interest-free loans to a subsidiary. It references compliance with stock exchange listing rules and regulatory guidelines. The content is a formal opinion statement by independent directors rather than a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a notice of voting results or a general regulatory filing. The document fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company decisions.
2022-10-26 Chinese
关于使用募集资金向全资子公司提供无息借款实施募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of raised funds (募集资金) by the company to provide an interest-free loan to its wholly-owned subsidiary for investment projects. It details the approval by the board and supervisory committee, the amount of funds raised, the purpose of the loan, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document is a formal disclosure about a financing activity related to the use of capital raised from a public offering. It does not contain financial statements or comprehensive financial data, nor is it a report or transcript. It is not a simple announcement of a report publication but a substantive announcement about capital use. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3445 characters, which is relatively short but contains detailed information about the financing activity, not just a notice or certification.
2022-10-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.